Adherence to antiretroviral therapy for HIV in sub‐Saharan Africa and Asia: a comparative analysis of two regional cohorts

Abstract

Introduction: Our understanding of how to achieve optimal long-term adherence to antiretroviral therapy (ART) in settings where the burden of HIV disease is highest remains limited. We compared levels and determinants of adherence over time between HIV-positive persons receiving ART who were enrolled in a bi-regional cohort in sub-Saharan Africa and Asia. Methods: This multicentre prospective study of adults starting first-line ART assessed patient-reported adherence at follow-up clinic visits using a 30-day visual analogue scale. Determinants of suboptimal adherence (<95%) were assessed for six-month intervals, using generalized estimating equations multivariable logistic regression with multiple imputations. Region of residence (Africa vs. Asia) was assessed as a potential effect modifier. Results: Of 13,001 adherence assessments in 3934 participants during the first 24 months of ART, 6.4% (837) were suboptimal, with 7.3% (619/8484) in the African cohort versus 4.8% (218/4517) in the Asian cohort (p < 0.001). In the African cohort, determinants of suboptimal adherence were male sex (odds ratio (OR) 1.27, 95% confidence interval (CI) 1.06–1.53; p = 0.009), younger age (OR 0.8 per 10 year increase; 0.8–0.9; p = 0.003), use of concomitant medication (OR 1.8, 1.0–3.2; p = 0.044) and attending a public facility (OR 1.3, 95% CI 1.1–1.7; p = 0.004). In the Asian cohort, adherence was higher in men who have sex with men (OR for suboptimal adherence 0.6, 95% CI 0.4–0.9; p = 0.029) and lower in injecting drug users (OR for suboptimal adherence 1.6, 95% CI 0.9–2.6; p = 0.075), compared to heterosexuals. Risk of suboptimal adherence decreased with longer ART duration in both regions. Participants in low- and lower-middle-income countries had a higher risk of suboptimal adherence (OR 1.6, 1.3–2.0; p < 0.001), compared to those in upper-middle or high-income countries. Suboptimal adherence was strongly associated with virological failure, in Africa (OR 5.8, 95% CI 4.3–7.7; p < 0.001) and Asia (OR 9.0, 95% CI 5.0–16.2; p < 0.001). Patient-reported adherence barriers among African participants included scheduling demands, drug stockouts, forgetfulness, sickness or adverse events, stigma or depression, regimen complexity and pill burden. Conclusions: Psychosocial factors and health system resources may explain regional differences. Adherence-enhancing interventions should address patient-reported barriers tailored to local settings, prioritizing the first years of ART.

Rheumatic Heart Disease Treatment Cascade in Uganda

“…The age effect was also seen, however, in a previous report from the UHI 5 . These findings contrast with the HIV literature since a large multi-center African study suggested that ART adherence improves with age 26 .…”

Adherence to antiretroviral therapy among HIV/AIDS patients in the context of early treatment initiation in Vietnam

“…The regression model showed that female patients were more likely to comply with treatment regimens. The result was in line with various studies in China, 20 sub-Saharan Africa, and Asia, 21 while contradictory results were affirmed in several studies in the USA, 22 British Columbia, and Canada. 23 The heterogeneity across studies, perhaps, could be explained by the sociocultural differences.…”

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

“…Broader dosing intervals are of real potential benefit with current ARV treatments as, when initiated, patient adherence to the offered regimen is imperative, otherwise resistance patterns will rapidly emerge. Unfortunately, for a broad range of reasons that include access limitations, stigma, cost, substance abuse, absorption abnormalities, and comorbidities, patients often do not adhere to regimen recommendations [ 8 , 11 , 46 , 47 ]. While LAP therapeutics will soon become available, they most likely will have a specific niche due, in part, to limitations associated with large injection volumes, injection site reactions, and suboptimal dosing intervals [ 25 , 48 ].…”